Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions
Rhea-AI Summary
Globus Medical (NYSE: GMED) announced the acquisition of Durham, NC-based Higgs Boson Health, a digital healthcare experience company incubated out of Duke University. Higgs Boson focuses on AI-driven software to enhance patient and provider experience across the full episode of care.
According to Globus Medical, Higgs Boson’s teams of software developers and AI scientists will join the company to support its vision of a seamless digital healthcare environment. The technology is intended to strengthen Globus Medical’s surgical intelligence pillar by integrating outcomes and analytics along the patient journey, with the stated long-term goal of improving musculoskeletal surgery outcomes.
Positive
- Acquisition of Higgs Boson Health expands digital and AI capabilities across care episode
- Experienced AI and software teams added to support surgical intelligence vision
- Technology integrated into Globus ecosystem to enhance outcomes and analytics platform
Negative
- None.
News Explained
The announcement provides no disclosed price or closing terms, so no current economic or ownership change for common holders is established.
On
Because the release gives neither purchase consideration nor closing conditions, the transaction’s economics and completion status cannot yet be assessed from this disclosure.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Second-quarter earnings | Positive | +1.6% | Sales grew and non-GAAP EPS guidance increased; shares rose 1.57%. |
| Jul 16 | Earnings scheduling | Neutral | -4.8% | Routine earnings timing announcement preceded a 4.83% share-price decline. |
| May 07 | First-quarter earnings | Positive | -8.4% | Sales and earnings increased, but shares declined 8.37%. |
| Apr 16 | Earnings scheduling | Neutral | +2.7% | Routine first-quarter reporting schedule preceded a 2.68% share-price gain. |
| Mar 23 | Board departure | Negative | -1.1% | Director John A. DeFord stepped down; shares declined 1.1%. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
GMED's recent positive earnings announcements produced mixed outcomes, with one positive reaction and one sharp negative divergence.
Key Terms
musculoskeletal medical
episode of care medical
closed-loop technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care.
“Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient’s journey through our healthcare system while enhancing real-time information and surgical intelligence available to healthcare providers with the ultimate goal of getting to
“The acquisition of Higgs Boson and its digital solutions represents the next step in our strategy of enhancing the Globus ecosystem,” commented Keith Pfeil, President and Chief Executive Officer. “As we continue to build out the ecosystem, the Higgs Boson technology will be part of our surgical intelligence pillar, bringing together outcomes and analytics in a closed-loop manner that fosters continuous learning, integrating along the full patient journey with the goal of improving patient outcomes.”
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.
Contact:
Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com
